Frazier Life Sciences Management L.P. Has $26.59 Million Stake in Savara Inc (NASDAQ:SVRA)

Frazier Life Sciences Management L.P. boosted its stake in Savara Inc (NASDAQ:SVRA - Free Report) by 6.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,660,379 shares of the company's stock after purchasing an additional 502,994 shares during the period. Savara comprises approximately 1.1% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 22nd biggest position. Frazier Life Sciences Management L.P. owned approximately 5.05% of Savara worth $26,587,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cibc World Markets Corp acquired a new stake in Savara in the fourth quarter valued at $33,000. XTX Topco Ltd acquired a new stake in Savara in the fourth quarter valued at $34,000. Ameriprise Financial Inc. acquired a new stake in Savara in the fourth quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new stake in Savara in the fourth quarter valued at $41,000. Finally, Hsbc Holdings PLC acquired a new stake in Savara in the fourth quarter valued at $48,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Savara has an average rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Price Performance

SVRA stock opened at $3.13 on Wednesday. The stock has a market capitalization of $540.98 million, a PE ratio of -7.28 and a beta of 0.44. The company's 50-day moving average is $2.96 and its 200-day moving average is $3.01. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). Equities research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.